Thyas Obtains Exclusive Rights to Manufacture Induced Pluripotent Stem Cells-Derived Killer T Cells for Autologous Immunotherapy KYOTO, Japan, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Thyas Co. Ltd. (Thyas) signed a licensing agreement with iPS Academia Japan, Inc. (iPS-AJ), a technology licensing organization of induced pluripotent...